Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date

Biosimilar Now Accepted For Filing With Three Major Regulators

 
• By Dean Rudge
  
China USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
Bio-Thera Solutions is looking to break into the blockbuster US bevacizumab market as part of its global strategy. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products